Table 1.
Patient characteristics
| Total | Chronic phase CML | Accelerated phase CML | |
|---|---|---|---|
| Patient number | 165 | 127 | 38 |
| Age (y), median (range) | 42 (20–74) | 43 (20–70) | 38.5 (21–74) |
| Male, n (%) | 110 (66.7) | 79 (62.2) | 31 (81.6) |
| ECOG performance status, n (%) | |||
| 0 | 99 (60.0) | 82 (64.6) | 17 (44.7) |
| 1 | 64 (38.8) | 43 (33.9) | 21 (55.3) |
| Not done | 2 (1.2) | 2 (1.6) | 0 |
| Time from diagnosis to olverembatinib treatment (y), median (range) | 5.7 (0.3–23.2) | 5.3 (0.6–23.2) | 6.9 (0.3–14.7) |
| Prior TKIs, n (%) | |||
| Imatinib | 22 (13.3) | 16 (12.6) | 6 (15.8) |
| Imatinib/dasatinib | 60 (36.4) | 47 (37.0) | 13 (34.2) |
| Imatinib/nilotinib | 26 (15.8) | 22 (17.3) | 4 (10.5) |
| Imatinib/dasatinib/nilotinib | 45 (27.3) | 35 (27.6) | 10 (26.3) |
| Nilotinib | 6 (3.6) | 4 (3.1) | 2 (5.3) |
| Dasatinib | 2 (1.2) | 1 (0.8) | 1 (2.6) |
| Dasatinib/nilotinib | 4 (2.4) | 2 (1.6) | 2 (5.3) |
| Number of lines of prior TKI therapy, n (%) | |||
| 1 | 30 (18.2) | 21 (16.5) | 9 (23.7) |
| 2 | 90 (54.5) | 71 (55.9) | 19 (50.0) |
| ≥ 3 | 45 (27.3) | 35 (27.6) | 10 (26.3) |
| BCR-ABL1 mutation status by Sanger sequencing, n (%) | |||
| No mutation | 24 (14.5) | 23 (18.1) | 1 (2.6) |
| T315I single mutation | 102 (61.8) | 77 (60.6) | 25 (65.8) |
| T315I + additional mutations | 25 (15.2) | 16 (12.6) | 9 (23.7) |
| Other mutations | 14 (8.5) | 11 (8.7) | 3 (7.9) |
| BCR-ABL1 mutation status by next-generation sequencing, n (%) | |||
| No mutation | 20 (16.9) | 19 (20.2) | 1 (4.2) |
| T315I single mutation | 53 (44.9) | 41 (43.6) | 12 (50.0) |
| T315I + additional mutations | 19 (16.1) | 15 (16.0) | 4 (16.7) |
| Other mutations | 14 (11.9) | 12 (12.8) | 2 (8.3) |
| Compound mutations | 12 (10.2) | 7 (7.4) | 5 (20.8) |
| ACA, n (%) | |||
| Yes | 28 (17.0) | 10 (7.9) | 18 (47.4) |
| No | 137 (83.0) | 117 (92.1) | 20 (52.6) |
ACA additional chromosomal abnormalities, CML chronic myeloid leukemia, ECOG Eastern Cooperative Oncology Group, TKI tyrosine kinase inhibitor